|
 |
AlemtuzumabThis page contains recent news articles, when available, and an overview of Alemtuzumab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Alemtuzumab (when available) Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. For treatment of B-cell chronic lymphocytic leukemia Mechanism Of Action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. News Articles on Alemtuzumab Arzerra for Refractory Leukemia Cleared by the FDA - Nov 9, 2009 ...is indicated to treat patients with chronic lymphocytic leukemia that is resistant to fludarabine and alemtuzumab, the standard treatment options. ... FDA news (subscription) GSK and Genmab Receive Accelerated Approval for Arzerra - Oct 26, 2009 The approval is based on results from a pivotal study in which 42% of patients with CLL who were refractory to both fludarabine and alemtuzumab (two ... Reuters FDA Grants Accelerated Approval to Ofatumumab for Refractory Chronic ... - Oct 27, 2009 The approval is based on results from a pivotal study in which 42% of patients with CLL who were refractory to both fludarabine and alemtuzumab responded to ... DG News Genmab Achieves Milestone in Arzerra Collaboration - Oct 26, 2009 GSK for the FDA approval of Arzerra for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. ... Reuters More Tysabri Problems; Time for a Biogen-Idec Credibility Check - Oct 30, 2009 Currently Natalizumab is the focal point of interest throughout the world, but [that] other new drugs, such as Alemtuzumab or anti-CD20 antibodies may soon ... BNET Affordable anti-rejection drug effective - Oct 19, 2009 The scientists looked at the two most common drugs used for induction immunosuppression therapy with kidney and pancreas transplants -- alemtuzumab, ... United Press International Genmab shares slide as US facility goes up for sale - Nov 6, 2009 ...lymphocytic leukaemia as a treatment for patients who have not responded to Genzyme Corp's Campath (alemtuzumab) or the chemotherapy fludarabine. ... Pharma Times Genzyme Corporation Q3 2009 Earnings Call Transcript - Oct 21, 2009 The alemtuzumab for campus MS program is making good progress. We reported on four year results now on the Phase II trial, but we also announced the Phase ... Seeking Alpha (blog) Lonza wins contract for Genmab/GSK's Arzerra - Nov 12, 2009 Arzerra was granted accelerated approval in the US on October 26 for use in patients with CLL that is refractory to fludarabine and alemtuzumab. ... Pharmafocus Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP ... - Nov 3, 2009 ...in drug development has led to several approvals of important products including oncology therapies Velcade (bortezomib) and Campath (alemtuzumab). ... Reuters Genmab to Present Data from Multiple Studies at ASH - Nov 11, 2009 Ofatumumab is approved in the US for treatment of chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. Ofatumumab is not approved ... PharmaLive (press release) (subscription) Summary: - Genmab Announces Results for the Nine Months Period of 2009 - Nov 10, 2009 In October, we received accelerated approval for Arzerra from the FDA for CLL that is refractory to fludarabine and alemtuzumab. The FDA approval triggered ... Ad-Hoc-News (Pressemitteilung) Genmab/GlaxoSmithKline: first approval for Arzerra - Oct 28, 2009 ...on a pivotal study involving 225 chronic lymphocytic leukemia (CLL) patients who were refractory to both fludarabine and Campath (alemtuzumab; Genzyme). ... Trading Markets (press release) Genmab to Sell Manufacturing Facility and Cut 300 Jobs - Nov 5, 2009 ...human CD20 antibody, Arzerraâ„¢, as a treatment for patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. ... Genetic Engineering News (press release) Arzerraâ„¢ Approved for Refractory Chronic Lymphocytic Leukemia - Nov 2, 2009 ...for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). ... Cancer Consultants Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson ... - Nov 5, 2009 ...from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. ... Pharmaceutical Technology Magazine Genzyme: Focusing on Lumizyme Approval - Oct 30, 2009 I continue to value alemtuzumab in multiple sclerosis as before, but have lowered my probability of success and expected launch year for mipomersen in ... Seeking Alpha (blog) Genzyme Reports Third-Quarter Financial Results - Oct 22, 2009 Genzyme's alemtuzumab for multiple sclerosis showed a durable treatment benefit in a review of four-year phase 2 trial data, which was presented at the ... Business Wire (press release) Sclerosi multipla: il trattamento con Alemtuzumab è efficace ma può comportare ... - Oct 21, 2009 In un recente studio clinico di fase II, il trattamento con Alemtuzumab si è mostrato efficace in pazienti con forme iniziali di sclerosi multipla ... Fondazione Serono FDA, GSK/Genmabì?˜ 백혈병 ì¹˜ë£Œì œ 허가 - Oct 28, 2009 ...기존 약물ì?¸ Genzyme사ì?˜ Campath(alemtuzumab)나 í™”í•™ìš”ë²•ì œ fludarabineì—? ë°˜ì?‘하지 않는 환ìž? 치료ì—? 허가한 것ì?´ë‹¤. ì•Œì œë?¼ëŠ” 모노í?¬ë¡œë‚ í•ì²´ë¡œ 우리 몸ì?˜ ë©´ì— ... 메디포뉴스 GSK y Genmab reciben la aprobación acelerada de la FDA de ARZERRA® para la ... - Oct 30, 2009 La aprobación se basa en los resultados de un estudio pivotal en el que un 42% de los pacientes con LLC, refractarios tanto a fludarabina como a alemtuzumab ... acceso.com (Comunicado de prensa) FDA одобри ofatumumab за лечение на рефрактерна хронична лимфоцитна левкемиÑ? ... - Nov 1, 2009 одобри ofatumumab (Arzerra, GlaxoSmithKline) за лечение на пациенти Ñ? хронична лимфоцитна левкемиÑ?, неподдаваща Ñ?е на терапиÑ? Ñ? fludarabine alemtuzumab. ... DoctorBG.com GSK 백혈병 ì¹˜ë£Œì œ 'ì•„ì œë?¼' 승ì?¸ - Oct 29, 2009 ...ì•„ì œë?¼ëŠ” 플루다ë?¼ë¹ˆ(fludarabine)ê³¼ ì•Œë ˜íˆ¬ì£¼ë§µ(alemtuzumab)으로 치료ì—? 실패한 만성 림프구성 백혈병 환ìž? ë°? 플루다ë?¼ë¹ˆë¡œ 치료ì—? 실패한 환ìž?와 종양ì?´ 커 ì•Œë ˜íˆ¬ ... 헬스코리아뉴스 Arzerra® aprovado pela FDA para tratamento da leucemia linfocÃtica crónica - Oct 27, 2009 ...em doentes que não respondem à terapêutica com Campath® (alemtuzumab) da Genzyme Corp ou com a quimioterapia fludarabina, noticia o site PharmaTimes. ... POP - Portal de Oncologia Portugês Genzyme Appears Overbought: Reiterating Near-Term Sell - Aug 27, 2009 Lastly, I continue to view the real growth engine for Genzyme to be related to Lumizyme, alemtuzumab and mipomersen, not the upcoming quarterly results. Seeking Alpha Genzyme Corp. Reports Operating Results (10-Q) - Aug 10, 2009 The contingent consideration obligations are net of the continued funding expected to be received from Bayer for the development of alemtuzumab for MS. GuruFocus.com About this author: - Aug 6, 2009 The most promising being alemtuzumab in MS and mipomersen in high-risk hypercholesterolemia. I view these drugs to be essential to Genzyme's long-term Seeking Alpha About this author: - Aug 11, 2009 Very good late stage pipeline with alemtuzumab (MS), mipomersen (lower LDL), Lumizyme (Myozyme follow-up - it's a long story). Seeking Alpha Trends in Leukemia - Aug 21, 2009 The prognosis is poor for patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab (double-refractory CLL) or refractory American Journal of Hemotology and Oncology Keeping things simple - Aug 6, 2009 ...to more exciting drugs and combinations, such as fludarabine/rituximab (Rituxan, Genentech) … fludarabine/cyclophosphamide/rituximab … alemtuzumab (Campath, HemOncToday DJ DGAP-Adhoc: Genmab Announces 2009 First Half Year Results - Aug 18, 2009 CLL whose disease is refractory to fludarabine and alemtuzumab - The FDA extended the action date for the ofatumumab BLA by three months to October 31, VisAvis (Pressemitteilung) Scleroza în plăci ÅŸi medicamentul speranÅ£ei - Aug 16, 2009 Dacă pe de o parte pacienÅ£ii trataÅ£i cu alemtuzumab au înregistrat o scădere cu 73 la sută a recidivelor faţă de pacienÅ£ii trataÅ£i cu Interferon beta, Anima News New Report Just Published Stakeholder Insight: Chronic Leukemias ... - 13 Jul 2009 Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering). Gleevec is firmly established as the Live-PR.com (Pressemitteilung) Genmab completes patient recruitment in ofatumumab pivotal CLL study - Jul 10, 2009 A total of 220 patients have been enrolled in the study including 100 patients refractory to fludarabine and alemtuzumab, 100 patients who are refractory to pharmabiz.com Identifying alemtuzumab as an anti-myeloid cell antiangiogenic ... - Jun 19, 2009 We performed qRT-PCR and FACS on human VLC to assess the expression of the CD52 antigen, the target of the immunotherapeutic Alemtuzumab. 7thSpace Interactive (press release) DJ DGAP-Adhoc: Recruitment Completed in Arzerra? (Ofatumumab ... - Jul 9, 2009 A total of 220 patients have been enrolled in the study including 100 patients refractory to fludarabine and alemtuzumab, 100 patients who are refractory to VisAvis (Pressemitteilung) Alemtuzumab dopo terapia con farmaci antileucemici: 6 pazienti morti - Jun 24, 2009 Mercoledì 24 Giugno 2009 - Health Canada ha informato i medici ei pazienti riguardo a problemi di sicurezza insorti con l'uso di MabCampath ( Alemtuzumab XagenaSalute Sclerosi multipla recidivante-remittente: gravi effetti ... - Jun 23, 2009 Fin dal 1991 gli studi su Alemtuzumab ( Campath, MabCampath ) nel trattamento dei pazienti con sclerosi multipla secondaria progressiva hanno indicato che XagenaSalute MabCampath associato a gravi reazioni avverse nella sclerosi ... - Jun 17, 2009 Lo studio di fase 2 ha mostrato che i pazienti trattati con Alemtuzumab hanno presentato una riduzione del 74% dell'incidenza di recidive e una riduzione XagenaSalute GSK í•ì•”ì œ 'ì•„ì œë?¼' 美 발매 지연 - Jun 17, 2009 ...ì•„ì œë?¼ëŠ” GSKê°€ 지난 2006ë…„ 12ì›” ì 맵으로부터 ì „ì„¸ê³„ íŒ?권ì?„ ë?„ìž…í•œ 약물로, 올해 1ì›” ë§? '플루다ë?¼ë¹ˆ'(fludarabine), 'ìº íŒ¨ìŠ¤'(Campath, alemtuzumab) 치료ì—? ë°˜ì?‘ 메디파나뉴스 ΣκλήÏ?υνση Κατά Πλάκας: Τι νεώτεÏ?ο υπάÏ?χει - Jun 19, 2009 Από αυτά χοÏ?ηγοÏ?νται από το στόμα τα cladribine, teriflunomide, FTY720, fumaric acid, laquinimod και ενÎσιμα τα alemtuzumab, rituximab, atacicept. Ιατροnet Neurologia - postÄ™py 2008 - Jun 22, 2009 CAMMS223 Trial Investigators: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med., 2008; 359: 1786-1801 25. Kappos L., Gold R., Medycyna Praktyczna Genzyme to acquire worldwide rights of multiple sclerosis drug ... - Mar 31, 2009 ...(GENZ: News ) Tuesday announced an agreement with Bayer HealthCare to acquire the worldwide rights of Campath, or alemtuzumab. The deal will give Genzyme RTT News Genzyme acquires rights to multiple sclerosis drug from Bayer - Apr 2, 2009 Bayer will continue to fund a portion of alemtuzumab's development in multiple sclerosis (MS) and will retain an option to co-promote the product in MS upon Pharmaceutical Business Review Company and People Notes: BMS and Otsuka Extend Abilify Agreement ... - Apr 9, 2009 Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to copromote the product in MS upon approval. Pharmaceutical Technology Magazine Biogen Idec Beats on Earnings but Misses on Revenues in Q1 - Apr 17, 2009 ...while Phase III programs are under way with MS drugs alemtuzumab (Genzyme Corp. and Bayer AG), fingolimod (Novartis AG), dirucotide (BioMS Medical Corp. BioWorld Online Monoclonal antibody cancer therapy - Apr 5, 2009 Alemtuzumab (Campath) is an antibody drug approved for another type of leukemia, called B cell chronic lymphocytic leukemia (CLL). Alemtuzumab, based on an News-Medical.net StandoutStocks.com: "Stocks that Standout" picks for today are ... - Mar 31, 2009 Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to co-promote the product in MS upon approval. TMCnet 肾移æ¤?å?ŽAlemtuzumabå’ŒSirolimus治疗方案ä¸Tacrolimusæ—©æœŸä½¿ç”¨ä»¥é˜²æ¢ ... - Apr 15, 2009 ...医å¦ç©ºé—´ï¼ˆMEDcyber.com）4月16日消æ?¯â€”近期å?‘表在《American Journal of Transplantationã€‹ä¸Šçš„ä¸€ç¯‡æ–‡ç« æŠ¥é?“了异体肾移æ¤?å?ŽAlemtuzumab诱导治疗和Sirolimusç»´æŒ?æ²»ç–—ä¸ 医学空间 Genzyme adquiere la cartera de productos de oncologÃa hematológica ... - Apr 16, 2009 Bayer continuará financiando una parte del desarrollo de alemtuzumab en esclerosis múltiple y conservará la opción de promocionar conjuntamente el producto Mercado Bayer verkauft Blutkrebs-Präparate an US-Konzern Genzyme - Mar 31, 2009 Zudem vereinbarten Bayer und Genzyme, ihre Entwicklungskooperation bei dem Wirkstoff Alemtuzumab gegen Multiple Sklerose fortzusetzen. Reuters Deutschland Siglato accordo strategico fra Genzyme e Bayer - Apr 2, 2009 ...“Alemtuzumab potrà diventare una terapia per il trattamento della Sclerosi Multipla, ed una parte importante del nostro futuro. Bologna 2000 Genzyme compra productos oncológicos de Bayer - Apr 8, 2009 ...sobre los derechos de desarrollo y distribución mundial de tres productos; Campath (alemtuzumab), Fludara (fludarabina) y Leukine (sargramostim). Invertia (Chile) Genzyme acuerda la compra de dos productos al área de ... - Apr 6, 2009 Supone asà mismo una gran responsabilidad para Genzyme, que pasa a liderar los actuales ensayos clÃnicos con alemtuzumab de fase III en esclerosis múltiple Salut i Força Wall Street schließt fest - GM-Wert in zwei Tagen halbiert - Mar 31, 2009 ...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs "Alemtuzumab" gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung Wall Street mit Kurserholung erwartet - Mar 31, 2009 ...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs "Alemtuzumab" gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung MS hastalığı için antikor üretildi - Mar 31, 2009 Dr. Croze, bir tür monoklonal antikor (yapay antikor) olan Alemtuzumab’ın erken teÅŸhiste kullanıldığında hastalığın yol açtığı özürlü durumun önüne Hürriyet 拜耳與Genzymeé?”æˆ?戰略å?”è° - Mar 31, 2009 ...拜耳還將把雙方å?ˆä½œé–‹ç™¼çš„多發性硬化症藥物Alemtuzumabçš„å…¨ç?ƒé–‹ç™¼èˆ‡åˆ†éŠ·æ¬Šåˆ©è¿”還給Genzyme。該藥目å‰?ä»?處於開發階段。 拜耳表示，兩公å?¸å°‡ç¹¼çºŒå®ƒå€‘在Alemtuzumab上的 新浪網 DAX Schluss: Deutliche Erholung, Commerzbank mit an der Spitze - Mar 31, 2009 Die beiden Unternehmen setzen ihre bestehende Entwicklungskooperation bei dem Wirkstoff Alemtuzumab gegen MS fort. Die Lizenz für die weltweite Vermarktung AktienCheck Blick auf die Märkte - Mar 31, 2009 ...mehrerer Onkologie-Produkte von Bayer sowie die weitere Entwicklung und Vermarktung des Wirkstoffs „Alemtuzumab“ gegen Multiple Sklerose (MS) getroffen. Frankfurter Allgemeine Zeitung New Guidelines Issued for Blood Cancer Treatment - 18 Mar 2009 ...use of Campath® (alemtuzumab) as a first-line therapy for the treatment of B-cell chronic lymphocytic leukemia (CLL) in its recent updated guidelines. PharmaLive.com (press release) Application Submitted for New Drug to Treat Advanced Stage CLL - Mar 2, 2009 The drug was 47% effective in patients resistant to fludarabine treatment and considered inappropriate candidates for alemtuzumab. Oncology Nursing News Azaya Therapeutics Initiates Collaboration in Nanoparticle ... - Mar 10, 2009 ...several key executive positions with Ilex Oncology, Inc. and was instrumental in the development and approval of the ILEX drug, Campath (alemtuzumab). Nanotechwire.com What do you know about new MS treatment? - Feb 25, 2009 Campath 1H is the brand name of a monoclonal antibody known as alemtuzumab. This drug is used in treatment of B cell chronic lymphocytic leukemia (B-CLL) CNN Stammzellentransplantation bei schubförmiger MS - ermutigende ... - Feb 28, 2009 The Lancet Neurology publizierten Phase-Ib/IIa-Studie erhielten Patienten ein milderes Konditionierungsverfahren mit Cyclophophamid und Alemtuzumab bzw. Medizin-Aspekte Brand Names/Synonyms: Alemtuzumab is also known by the following brand names and/or synonyms: Campath; Campath (ILEX Pharmaceuticals LP) Drug Category: Alemtuzumab is categorized under the following by the FDA: Antineoplastic Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Humanized anti-CD52 antibody |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
